Martin J. Brodie

Martin J. Brodie

Auto-generated profile, based on publicly available information

Martin J. Brodie

Department of Medicine and Clinical Pharmacology University of Glasgow Glasgow UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Epilepsia
Verified
Journal Article
Open access
PDF file
PKPavel Klein
Pavel Klein
RDRaymond Dingledine
Raymond Dingledine
EAEleonora Aronica
Eleonora Aronica
CBChristophe Bernard
Christophe Bernard
IBIngmar Blumcke
Ingmar Blumcke
Wolfgang LöscherWolfgang Löscher
Wolfgang Löscher
Summary: The most common forms of acquired epilepsies arise following acute brain insults such as traumatic brain injury, stroke, or central nervous system infections. Treatment is effective for only 60%‐70% of patients and remains symptomatic despite decades of effort to develop epilepsy prevention therapies. Recent preclinical efforts are focused on likely primary drivers of epileptogenesis, namely inflammation, neuron loss, plasticity, and circuit reorganization. This review suggests a path to identify neuronal and molecular targets for clinical testing of specific hypotheses about epileptogenesis and its prevention or modification. Acquired human epilepsies with different etiologies share some features with animal models. We identify these commonalities and discuss their relevance to the development of successful epilepsy prevention or disease modification strategies. Risk factors for developing epilepsy that appear common to multiple acute injury etiologies include intracranial bleeding, disruption of the blood‐brain barrier, more severe injury, and early seizures within 1 week of injury. In diverse human epilepsies and animal models, seizures appear to propagate within a limbic or thalamocortical/corticocortical network. Common histopathologic features of epilepsy of diverse and mostly focal origin are microglial activation and astrogliosis, heterotopic neurons in the white matter, loss of neurons, and the presence of inflammatory cellular infiltrates. Astrocytes exhibit smaller K+conductances and lose gap junction coupling in many animal models as well as in sclerotic hippocampi from temporal lobe epilepsy patients. There is increasing evidence that epilepsy can be prevented or aborted in preclinical animal models of acquired epilepsy by interfering with processes that appear common to multiple acute injury etiologies, for example, in post–status epilepticus models of focal epilepsy by transient treatment with a trkB/PLCγ1 inhibitor, isoflurane, orHMGB1 antibodies and by topical administration of adenosine, in the cortical fluid percussion injury model by focal cooling, and in the albumin posttraumatic epilepsy model by losartan. Preclinical studies further highlight the roles ofmTOR1 pathways,JAK‐STAT3,IL‐1R/TLR4 signaling, and other inflammatory pathways in the genesis or modulation of epilepsy after brain injury. The wealth of commonalities, diversity of molecular targets identified preclinically, and likely multidimensional nature of epileptogenesis argue for a combinatorial strategy in prevention therapy. Going forward, the identification of impending epilepsy biomarkers to allow better patient selection, together with better alignment with multisite preclinical trials in animal models, should guide the clinical testing of new hypotheses for epileptogenesis and its prevention.

1 July 2016 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
MBMartin J. Brodie
Martin J. Brodie
FBFrank Besag
Frank Besag
AEAlan B. Ettinger
Alan B. Ettinger
MMMarco Mula
Marco Mula
GGGabriella Gobbi
Gabriella Gobbi
BSBernhard J. Steinhoff
Bernhard J. Steinhoff
Antiepileptic drugs (AEDs) have many benefits but also many side effects, including aggression, agitation, and irritability, in some patients with epilepsy. This article offers a comprehensive summary of current understanding of aggressive behaviors in patients with epilepsy, including an evidence-based review of aggression during AED treatment. Aggression is seen in a minority of people with epilepsy. It is rarely seizure related but is interictal, sometimes occurring as part of complex psychiatric and behavioral comorbidities, and it is sometimes associated with AED treatment. We review the common neurotransmitter systems and brain regions implicated in both epilepsy and aggression, including the GABA, glutamate, serotonin, dopamine, and noradrenaline systems and the hippocampus, amygdala, prefrontal cortex, anterior cingulate cortex, and temporal lobes. Few controlled clinical studies have used behavioral measures to specifically examine aggression with AEDs, and most evidence comes from adverse event reporting from clinical and observational studies. A systematic approach was used to identify relevant publications, and we present a comprehensive, evidence-based summary of available data surrounding aggression-related behaviors with each of the currently available AEDs in both adults and in children/adolescents with epilepsy. A psychiatric history and history of a propensity toward aggression/anger should routinely be sought from patients, family members, and carers; its presence does not preclude the use of any specific AEDs, but those most likely to be implicated in these behaviors should be used with caution in such cases.

18 May 2017 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
MBMartin J. Brodie
Martin J. Brodie

5 December 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MMMarco Mula
Marco Mula
MBMartin J Brodie
Martin J Brodie
BTBertrand de Toffol
Bertrand de Toffol
AGAlla Guekht
Alla Guekht
HHHrvoje Hecimovic
Hrvoje Hecimovic
SWSarah Wilson
Sarah Wilson

6 March 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
AGAlla Guekht
Alla Guekht
MBMartin Brodie
Martin Brodie
MSMary Secco
Mary Secco
SLShichuo Li
Shichuo Li
NVNancy Volkers
Nancy Volkers
SWSamuel Wiebe
Samuel Wiebe

25 July 2018 in Epilepsia
Verified
Journal Article
Open access
PDF file
ARAlexandra Rohracher
Alexandra Rohracher
GZGeorg Johannes Zimmermann
Georg Johannes Zimmermann
VVVicente Villanueva
Vicente Villanueva
IGIñigo Garamendi
Iñigo Garamendi
JSJosemir W. Sander
Josemir W. Sander
ETEugen Trinka
Eugen Trinka
Summary: Objective: To pool observational data on the routine use of perampanel to obtain information on real‐world outcomes and data in populations typically underrepresented in clinical trials.Methods: Individual‐level data of people with epilepsy treated with perampanel at 45 European centers were merged into a single dataset. Prespecified outcomes were: 1‐year retention rate, 1‐year seizure freedom rate (duration ≥6 months), and incidence of treatment‐emergent adverse events (TEAEs). In addition, relationships were explored with logistic regression analyses.Results: The full analysis set comprised 2396 people: 95% had focal seizures; median epilepsy duration was 27 years; median number of concomitant antiepileptic drugs (AEDs) was 2; and median prior AEDs was 6. One‐year retention rate was 48% (1117/2332; 95% confidence interval [CI] 46‐50%), and 1‐year seizure‐free rate (≥6‐month duration) was 9.2% (74/803; 95% CI 7‐11%). Median treatment duration was 11.3 months (1832 patient‐years); median dose was 8 mg. In 388 individuals with available data at 3, 6, and 12 months, responder rates were 42%, 46%, and 39%, respectively. During the first year, TEAEs were reported in 68% of participants (1317/1497; 95% CI 66‐70%). Logistic regression found higher age at perampanel initiation was associated with higher seizure‐free rate, and higher number of prior AEDs with lower seizure‐free rate and lower rates of somatic TEAEs. In 135 individuals aged ≥65 years, 1‐year retention rate was 48% and seizure‐free rate was 28%.Significance: Across a large, treatment‐resistant population, add‐on perampanel was retained for ≥1 year by 48% of individuals, and 9% were seizure‐free for ≥6 months. TEAEs were in line with previous reports in routine clinical use, and less frequent than in the clinical trial setting. No new or unexpected TEAEs were seen. Despite the limitations of observational studies, our data indicate that some individuals may derive a marked benefit from the use of perampanel.